Cardiol Therapeutics appoints noted cardiologist Guillermo Torre-Amione as its new chairman

Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) (FRA:CT9) announced it had appointed Dr Guillermo Torre-Amione as the biotechnology company’s new board chair.

Torre-Amione, who has been an independent director of Cardiol since August 2018, is taking over from Dr Eldon Smith, who is retiring from the Board.

The new chair boasts a long career in cardiology, being board certified in cardiovascular disease and advanced heart failure and transplant cardiology. He was formerly the chief of the heart failure division and medical director of cardiac transplantation at the Houston Methodist DeBakey Heart & Vascular Center.

READ: Cardiol Therapeutics enrolls first patient in LANCER Phase II/III trial of CardiolRx on coronavirus patients

Torre-Amione is a professor of cardiology at The Methodist Hospital Research Institute, Houston, Professor of Medicine at the Weill Cornell Medical College of Cornell University, New York, and President of TecSalud in Mexico.

He has also spearheaded a number of clinical studies, including an FDA-approved Phase II clinical trial of neurostimulation in patients with advanced heart failure. Torre-Amione’s primary areas of research include heart failure, cardiac transplant, and the role of the immune response in modulating the progression of heart failure.

“I am pleased that Dr. Torre-Amione has agreed to serve as Chairman of our Board,” Cardiol CEO David Elsley said in a statement.

“Dr Torre-Amione’s exceptional knowledge of and expertise in both scientific and clinical research in heart failure, including the design and execution of pivotal clinical trials, will provide invaluable leadership and guidance during an exciting period of growth for Cardiol.”

“I am honored to be appointed chairman of Cardiol and to be given the opportunity to play an important role in the development of this extraordinary company,” Torre-Amione said.

“There is convincing evidence that inflammation plays an important role in the pathogenesis of heart failure and other cardiovascular disorders. Cardiol’s therapeutic strategy raises the exciting possibility of delivering an anti-inflammatory treatment to patients with heart failure that is not limited by toxicology concerns. As a cardiologist, I am excited to be part of this groundbreaking research.”

Elsley also thanked outgoing chair Eldon Smith for his “invaluable” contribution to the company, and wisehd him a “happy and healthy well-earned retirement” on behalf of the company and its board.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Story by ProactiveInvestors